Cargando…

Correction: Zhang et al. Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. Cancers 2021, 13, 6109

Detalles Bibliográficos
Autores principales:	Zhang, Dongyu, Shah, Neil J., Cook, Michael, Blackburn, Matthew, Serzan, Michael T., Advani, Shailesh, Potosky, Arnold L., Madhavan, Subha, Belouali, Anas, Atkins, Michael B., Braithwaite, Dejana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496993/ https://www.ncbi.nlm.nih.gov/pubmed/36139703 http://dx.doi.org/10.3390/cancers14184525

Ejemplares similares

Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis
por: Zhang, Dongyu, et al.
Publicado: (2021)

Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)—Their Incidence, Management, Multiorgan irAEs, and Rechallenge
por: Vaddepally, Raju, et al.
Publicado: (2022)

4401 Incidence, management, and outcomes of immune-related adverse events (irAEs): an analysis of a multidisciplinary toxicity team for cancer immunotherapy related irAEs
por: Balaji, Aanika, et al.
Publicado: (2020)

Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology
por: Naidoo, Jarushka, et al.
Publicado: (2023)

Editorial: Immune-related adverse Events (irAEs) of biopharmaceuticals
por: Batista-Duharte, Alexander, et al.
Publicado: (2023)

Impact of healthcare access and HIV testing on utilisation of cervical cancer screening among US women at high risk of HIV infection: cross-sectional analysis of 2016 BRFSS data
por: Zhang, Dongyu, et al.
Publicado: (2020)

Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies
por: Liu, Jing, et al.
Publicado: (2014)

Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
por: Albandar, Heidar J., et al.
Publicado: (2021)

Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection
por: Shah, Neil J., et al.
Publicado: (2019)

Development of an eHealth Tool for Capturing and Analyzing the Immune-related Adverse Events (irAEs) in Cancer Treatment
por: Moradian, Saeed, et al.
Publicado: (2023)

Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors
por: Teng, Yi-Shan, et al.
Publicado: (2023)

MicroRNA panels as diagnostic biomarkers for colorectal cancer: A systematic review and meta-analysis
por: Sur, Daniel, et al.
Publicado: (2022)

Invitation to tender R/I-6109/PS/PO
Publicado: (2022)

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
por: Kumar, Vivek, et al.
Publicado: (2017)

The role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs)
por: Ke, Wanhai, et al.
Publicado: (2020)

Corrigendum: Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
por: Kumar, Vivek, et al.
Publicado: (2017)

Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs
por: Eschweiler, Simon, et al.
Publicado: (2022)

BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma
por: Labadie, Brian W., et al.
Publicado: (2019)

Occurrence of Possible Rheumatologic Immune-Related Adverse Events (rh-irAEs) Associated with Immune Checkpoint Inhibitor (ICI) Therapy
por: Anjohrin, Suzanne, et al.
Publicado: (2021)

Reader Comment Regarding “Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management”
por: Sauder, Maxwell, et al.
Publicado: (2021)

Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)
por: Daban, A, et al.
Publicado: (2023)

Co Treatment With Biologic Agents and Immunotherapy in the Setting of irAEs of Difficult Management
por: Robles-Alonso, Virginia, et al.
Publicado: (2022)

Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) service
por: Abu-Shawer, Osama, et al.
Publicado: (2020)

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
por: Tarhini, Ahmad A, et al.
Publicado: (2021)

Current and emerging therapies for first line treatment of metastatic clear cell renal cell carcinoma
por: Serzan, Michael T., et al.
Publicado: (2021)

Immunotherapy-related adverse events (irAEs): extraction from FDA drug labels and comparative analysis
por: Wang, QuanQiu, et al.
Publicado: (2018)

Mobile Technologies and Cervical Cancer Screening in Low- and Middle-Income Countries: A Systematic Review
por: Zhang, Dongyu, et al.
Publicado: (2020)

Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer
por: Advani, Shailesh Mahesh, et al.
Publicado: (2019)

Ira
por: Petsko, Gregory A
Publicado: (2003)

Upper Gastrointestinal Tract IrAEs: A Case Report About Sintilimab-Induced Acute Erosive Hemorrhagic Gastritis
por: Ai, Qi, et al.
Publicado: (2022)

Association of Breast Density With Breast Cancer Risk Among Women Aged 65 Years or Older by Age Group and Body Mass Index
por: Advani, Shailesh M., et al.
Publicado: (2021)

Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy
por: Serzan, Michael T, et al.
Publicado: (2020)

Case Report: A Squamous Cell Lung Carcinoma Patient Who Responded to Neoadjuvant Immunochemotherapy but Died From Anastomosis Leakage or/and irAEs: Immune Microenvironment and Genomic Features Changes
por: Hao, Liping, et al.
Publicado: (2021)

Drugs in development for small cell lung cancer
por: Serzan, Michael T., et al.
Publicado: (2020)

Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti–PD-1 Monotherapy
por: Bai, Xue, et al.
Publicado: (2021)

The association between cognitive impairment and breast and colorectal cancer screening utilization
por: Yang, Shuang, et al.
Publicado: (2021)

Racial and ethnic inequities of palliative care use among advanced Non‐Small cell lung cancer patients in the US
por: Islam, Jessica Y., et al.
Publicado: (2022)

Analysis of Biological Aging and Risks of All-Cause and Cardiovascular Disease–Specific Death in Cancer Survivors
por: Zhang, Dongyu, et al.
Publicado: (2022)

Is education or income associated with insufficient fruit and vegetable intake among cancer survivors? A cross-sectional analysis of 2017 BRFSS data
por: Zhu, Zhikai, et al.
Publicado: (2020)

Construction of a prognostic model for HCC based on ferroptosis-related lncRNAs expression and its potential to predict the response and irAEs of immunotherapy
por: Dong, Liangbo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_43ujteqrtkl4qhba57virijl18